The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer
This is a prospective, multicenter, open-label study to observe the efficacy and safety of combination with radiotherapy, niraparib and toripalimab in patients With recurrent small cell lung cancer(SCLC).
Recurrent Small Cell Lung Cancer
RADIATION: SBRT|DRUG: Toripalimab|DRUG: Niraparib
ORR (Objective response rate), Objective response rate (ORR) evaluated by investigators and BIRC based on RECIST1.1, Approximately 2 years
DOR (Duration of Response), Duration of response (DOR) evaluated by investigators and BIRC based on RECIST1.1, Approximately 2 years|DCR (Disease of Response), Disease control rate (DCR) evaluated by investigators and BIRC based on RECIST1.1, Approximately 2 years|PFS (Progression Free Survival), Progression free survival (PFS) evaluated by investigators according to the response evaluation criteria in solid tumors (RECIST 1.1), Approximately 2 years|PFS (Progression Free Survival) Rate, PFS rates at 6-month（inestigators and BICR） and at 1-year, Approximately 1year|Overall suvival (OS), Overall suvival (OS), Approximately 2 years|OS (Overall Survival) rate, OS rates at 1 years, Approximately 1 years|Intrathoracic and extrathoracic recurrence rate, Approximately 2 years|The incidence of adverse events (AEs) as a measure of safety, An AE is any untoward medical occurrence in a patient or clinical investigation participant administered an investigational product. Safety and tolerance evaluated by incidence, severity and outcomes of AEs (according to NCI-CTCAE 5.0), Approximately 2 years
This is a prospective, multicenter, open-label study to observe the efficacy and safety of combination with radiotherapy, niraparib and toripalimab in patients With recurrent small cell lung cancer(SCLC).